Please or Register to create posts and topics.

Genomic Testing Basics: What PGx and NGx Results May Show

Genomic Testing Basics: What PGx and NGx Results May Show

Many people carry genetic variants that may influence how they respond to certain medications. (unless you have a specific citation with that figure). Getting to know the individual patient before making a plan is an old idea in medicine, and genomic testing is one of the newest ways to put it into practice. It's useful context for anyone reading about regenerative science, the Regenerative Protein Array (RPA) by Genesis Regenerative included.

Two kinds of genomic testing come up most often.

Pharmacogenomics, or PGx, looks at genes that affect how the body processes medications. A well-known example is an enzyme called CYP2D6, which converts codeine into its active form. People with a highly active version of the enzyme may convert the drug too quickly. People with a low-activity version may get little benefit from it. The prescription is the same, but the experience may be very different, and genetics is part of the reason. CYP2D6 belongs to a larger family of enzymes that together process a large share of common medications. And because a person's genes don't change, one test may stay useful for years as new prescriptions come up.

This isn't just theory. Large studies have linked pharmacogenommic-guided prescribing to improvements in certain medication-related outcomes in specific patient populations. Questions remain about which patients benefit most and about cost, but the evidence is encouraging.

Nutrigenomics, or NGx, looks at how genes may affect the way the body handles nutrients. Variants in a gene called MTHFR, for example, affect how the body processes folate. The evidence here is still developing. Many findings apply only to certain populations, and most nutrition-related traits involve many genes at once, along with diet and lifestyle. A single variant rarely tells the whole story, so nutrigenomic results are useful as one piece of information among several, not as a final answer.

So how might genomic results shape a regenerative plan? They don't choose a product or protocol. That decision belongs to the clinician and patient together. What testing may do is reduce the guesswork. It may flag medications that need a closer look, point to nutritional factors worth attention and give the clinician a fuller picture of the person before deciding on next steps.

Think of it as a starting point on a map. It shows where a specific patient begins, which is useful to know before anyone decides where to go.

To learn more about genomic testing, visit Genesis Regenerative at https://genesisregenerative.com/.